Trelegy Ellipta vs Xolair
Side-by-side cost comparison based on Medicare Part D data
Trelegy Ellipta
Fluticasone/Umeclidinium/Vilanterol
Manufactured by GlaxoSmithKline
Xolair
Omalizumab
Manufactured by Genentech/Novartis
Trelegy Ellipta costs 77% less per claim than Xolair ($380.00 vs $1,657.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Trelegy Ellipta | Xolair |
|---|---|---|
| Avg Cost Per Claim | $380.00 | $1,657.00 |
| Total Medicare Spending | $2.9B | $1.0B |
| Total Beneficiaries | 865,000 | 62,000 |
| Total Claims | 7,560,000 | 624,000 |
| Annual Cost/Patient | $3,325.00 | $16,677.00 |
| Year-over-Year Change | +19.8% | +5.4% |
| Generic Available | No | Yes |
| Patent Expiration | Sep 26, 2030 | Jun 20, 2017 |
| Manufacturer | GlaxoSmithKline | Genentech/Novartis |
| Condition | Asthma/COPD | Asthma/COPD |
| Generic Name | Fluticasone/Umeclidinium/Vilanterol | Omalizumab |
Trelegy Ellipta vs Xolair: What the Data Shows
Trelegy Ellipta (Fluticasone/Umeclidinium/Vilanterol) and Xolair (Omalizumab) are both used to treat asthma/copd. Based on Medicare Part D data, Trelegy Ellipta costs $380.00 per claim, which is 77% less than Xolair at $1,657.00 per claim.
Medicare spent $2.9B on Trelegy Ellipta and $1.0B on Xolair. In terms of patient reach, Trelegy Ellipta serves more beneficiaries (865,000 vs 62,000).
Year-over-year spending changed +19.8% for Trelegy Ellipta and +5.4% for Xolair. Trelegy Ellipta saw significant spending growth, suggesting increased utilization or price increases.
Xolair has a generic available, while Trelegy Ellipta remains brand-only until its patent expires Sep 26, 2030.
Frequently Asked Questions
Trelegy Ellipta is cheaper at $380.00 per claim, compared to $1,657.00 for Xolair. That makes Trelegy Ellipta about 77% less expensive per claim based on Medicare Part D data.
Yes, both Trelegy Ellipta and Xolair are used to treat asthma/copd. Your doctor can help determine which medication is more appropriate for your specific situation.
Xolair has a generic version (Omalizumab) available, which is typically much cheaper. Trelegy Ellipta is currently brand-only, with patent expiring Sep 26, 2030.
Medicare Part D spent $2.9B on Trelegy Ellipta covering 865,000 beneficiaries, and $1.0B on Xolair covering 62,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.